title: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer.
abstract: BACKGROUND
  We designed a prospective study to test epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) in resected stage I-IIIA non-small-cell lung cancer (NSCLC) and to correlate overexpression with survival.
  
  
  METHODS
  EGFR expression was evaluated in 130 consecutive NSCLC patients after radical surgery (60 squamous cell carcinomas, 48 adenocarcinomas, 22 large cell carcinomas: stage I, 41 (31%); stage II, 37 (29%) and stage IIIA, 52 (40%).
  
  
  RESULTS
  Overall, 101 of 130 (78%) specimens expressed EGFR, and with a cut-off value of 10% positive cells 48 cases (37%) were classified as positive. At univariate analysis, EGFR was significantly more expressed in stage III (50%) than stage I (20%) and stage II (25%) (P <0.03). No correlation with histotype was found. After a median follow-up of 84 months, both median survival time (18 versus 50 months), 2-year (43% versus 70%) and 5-year (31% versus 46%) survival rates of positive cases were significantly lower than negative ones [P <0.001; hazard ratio 1.96; 95% confidence interval (CI) 1.16-3.30]. At the multivariate analysis, EGFR overexpression and stage emerged as independent factors for cancer-related mortality.
  
  
  CONCLUSIONS
  In patients with radically resected stage I-IIIA NSCLC, EGFR overexpression predicts shorter survival, thus representing a valuable prognostic factor.
authors.affiliation: Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy. gselvaggi@inwind.it
authors.forename: G
authors.initials: G
authors.lastname: Selvaggi
authors.forename: S
authors.initials: S
authors.lastname: Novello
authors.forename: V
authors.initials: V
authors.lastname: Torri
authors.forename: E
authors.initials: E
authors.lastname: Leonardo
authors.forename: P
authors.initials: P
authors.lastname: De Giuli
authors.forename: P
authors.initials: P
authors.lastname: Borasio
authors.forename: C
authors.initials: C
authors.lastname: Mossetti
authors.forename: F
authors.initials: F
authors.lastname: Ardissone
authors.forename: P
authors.initials: P
authors.lastname: Lausi
authors.forename: G V
authors.initials: GV
authors.lastname: Scagliotti
mesh_terms: D000230:Adenocarcinoma / Q000503:physiopathology / Q000601:surgery; D000328:Adult; D000368:Aged; D018287:Carcinoma, Large Cell / Q000503:physiopathology / Q000601:surgery; D002289:Carcinoma, Non-Small-Cell Lung / Q000503:physiopathology / Q000601:surgery*; D002294:Carcinoma, Squamous Cell / Q000503:physiopathology / Q000601:surgery; D066246:ErbB Receptors / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000503:physiopathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D066246:ErbB Receptors